After almost 40 years, Sharon Finch will be stepping down from the PLG Board of Directors, which seems a good opportunity to hold a retrospective to look at how the deal making landscape has changed over this time, with views from big pharma, mid-cap and biotech.

Shaun Grady, Vice-President Business Development Operations at AstraZeneca, Paul Pay, ex CBO at Norgine and Dr Andy Richards CBE will provide their thoughts and experiences across 40 years of deal-making.